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ReviewHedgehog (Hh) signaling has emerged in recent years as
an attractive target for anticancer therapy because its
aberrant activation is implicated in several cancers. Ma-
jor progress has been made in the development of
SMOOTHENED (SMO) antagonists, although they have
shown several limitations due to downstream SMO
pathway activation or the occurrence of drug-resistant
SMO mutations. Recently, particular interest has been
elicited by the identification of molecules able to hit
glioma-associated oncogene (GLI) factors, the final effec-
tors of the Hh pathway, which provide a valid tool to
overcome anti-SMO resistance. Here, we review results
achieved in developing GLI antagonists, explaining their
mechanisms of action and highlighting their therapeutic
potential. We also underline the relevance of structural
details in their discovery and optimization.
Hh pathway and cancer
The evolutionarily conserved Hh pathway plays a crucial
role in patterning and organogenesis during early devel-
opment, in adult tissue maintenance and repairing func-
tions [1]. The Hh signaling represents a complex
transduction pathway orchestrated by several regulatory
components and post-translational events. A simplified
model of Hh signaling describes that in the absence of
Hh ligand (Sonic, Indian and Desert Hh), the PATCHED
receptor (PTCH) inhibits the class F G-protein-coupled
receptor (GPCR) SMO. When PTCH is engaged by Hh, it
relieves the inhibition of SMO and the signal is transduced
to the downstream transcription factors GLI1, GLI2, and
GLI3, which in turn regulate the expression of Hh target
genes involved in key cellular processes, such as cell cycle,
survival, migration, and metabolism [2]. Given the signif-
icant involvement of Hh signaling in the development
of several districts including pancreas, kidney, lung, ner-
vous system, and limb [3–5], its misregulation results in
multiple birth and developmental defects [6,7]. Aberrant
Hh pathway activation is responsible for the tumorigene-
sis of several disparate human cancers including0165-6147/
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basal cell carcinoma (BCC), and breast, lung, liver, stom-
ach, prostate, and pancreas tumors [8–11]. Hh-dependent
carcinogenesis may result from abnormal upregulation of
Hh ligands or deregulation of the expression or function
of downstream components such as loss of PTCH [12] or
suppressor of fused SUFU (the main negative regulator
of Hh signaling) [13], activating mutations of SMO [14],
amplification or chromosomal translocation of GLI1 [15],
GLI2 gene amplification, or stabilization of GLI2 protein.
Moreover, alterations of phosphorylation, ubiquitylation,
and acetylation post-translational processes can also con-
tribute to Hh-dependent tumorigenesis by modulating
GLI1 function [16–18]. Remarkably, Hh signaling is ac-
tive in cancer stem cells (CSCs) of various tumor types
[19,20], sustaining the proliferation of these niche cells
that are responsible for tumor relapse and resistance to
conventional anticancer therapy. Indeed, the Hh pathway
controls the functional properties of CSCs, such as self-
renewal, survival, metastatic spread, and neoangiogen-
esis by the regulation of stemness-determining genes such
as Nanog, often overexpressed in cancer. Given the in-
creasing evidences supporting the crucial role of the Hh
pathway in cancer initiation, proliferation, metastasis,
chemoresistance, and in the survival of CSCs [10,17],
its components represent attractive druggable targets
for anticancer therapy.
SMO antagonists: pitfalls and limitations
The first Hh inhibitor discovered was cyclopamine, a nat-
urally occurring alkaloid isolated from Veratrum californi-
cum [21], which inactivates SMO by directly binding to its
hepathelical bundle. Nevertheless, cyclopamine has shown
several limitations as a drug candidate, such as toxicity
and teratogenicity, poor oral bioavailability, and subopti-
mal pharmacokinetics with relatively short elimination
half-life [22].
In recent years, drug discovery efforts directed against
the Hh pathway have been focused predominantly on the
development of SMO antagonists and a remarkable num-
ber of small molecules of natural, semisynthetic or syn-
thetic origin have been developed and extensively reviewed
in recent reports [23–25]. Several SMO antagonists have
demonstrated efficacy in mouse xenografts and, most no-
tably, have been investigated in clinical trials against aTrends in Pharmacological Sciences xx (2015) 1–12 1
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Among them, vismodegib (GDC-0449/Erivedge) became
the first Hh inhibitor to receive approval from the USA
FDA in January 2012 for the treatment of locally advanced
or metastatic BCC [28].
Despite the initial enthusiasm, clinical development of
SMO antagonists has ultimately proved disappointing, due
to scarce pharmacokinetics, low selectivity on CSCs, severe
side effects, and the emergence of drug resistance. Indeed,
after an initial clinical response to treatment with vismo-
degib, a patient with metastatic MB showed tumor re-
growth within 3 months due to D473H point mutation
that rendered SMO insensitive to the drug [29]. Further-
more, acquired resistance has been also observed in BCC
patients under treatment with vismodegib and in a Phase I
study of saridegib (IPI-926). In this study, nine patients
with BCC, previously progressed on vismodegib, failed to
respond to saridegib, suggesting the existence of overlap-
ping mechanisms of resistance [30]. Recently, genomic
analysis of SMO resistance to vismodegib in BCC patients
has revealed a number of additional SMO mutations and
variants that confer constitutive activity and drug resis-
tance [31,32]. All variants have shown partial or complete
resistance to vismodegib, while the aPKC-i/l/GLI inhibitor
PSI and the GLI2 antagonist arsenic trioxide (ATO) were
both able to suppress Hh pathway activation in the pres-
ence of any SMO variants [31].
Several lines of evidence also suggest that cancer cells
can acquire resistance to SMO antagonists via SMO-inde-
pendent hyperactivation of the powerful downstream GLI
transcription factors, or mutations at different nodal
points of the Hh pathway. Indeed, preclinical and clinical
trials have shown that SMO drug resistance can be the
consequence of (i) GLI2 amplification during vismodegib or
sonidegib (LDE-225) treatment; (ii) upregulation of nonca-
nonical and synergistic GLI signaling [e.g., phosphoinosi-
tide 3-kinase (PI3K) pathway, observed during sonidegib
treatment]; and (iii) increase of the expression of ATP-
binding cassette transporters (ABCs), such as P-glycopro-
tein (Pgp), which diminishes drug efficacy by increasing its
cellular clearance [29,33–36].
Moreover, the onset and progression of some types of
Hh-driven cancers are related to Hh-pathway-activating
mutations downstream of SMO, such as loss of SUFU
or GLI1 amplification, thus rendering SMO antagonists
ineffective in these scenarios.
Not least, studies investigating systemic treatments
with SMO antagonists have revealed several side effects
including dysgeusia, alopecia, fatigue, nausea, diarrhea,
decreased appetite, hyponatremia, weight loss, and espe-
cially muscle cramping due to noncanonical SMO signaling
(SMO–AMP-activated protein kinase axis) and Ca2+ influx
[37,38].
Consequently, the development of Hh inhibitors that
modulate targets acting downstream of SMO or indepen-
dently by SMO, such as GLI, has recently emerged as a
more promising therapeutic strategy for the treatment of
Hh-dependent tumor. This approach would allow overcom-
ing anti-SMO resistance and adverse effects, which are
responsible for >50% dropouts rates in SMO antagonists
clinical trials.2GLI factors: new attractive targets in Hh-dependent
tumors
GLI transcription factors are the final effectors of the Hh
pathway and share common structural features, such as five
highly conserved tandem zinc fingers (ZFs), a fairly con-
served N-terminal domain, several potential protein kinase
A (PKA) binding sites, and additional conserved regions at
the C terminus. Nevertheless, GLI proteins exert different
functions in vivo: GLI1 acts only as a transcriptional activa-
tor, whereas GLI2 and GLI3 can act both as transcriptional
activators and as repressors, depending on the specific cell
context and on the activation state of Hh signaling. In
absence of upstream Hh signaling, some protein kinases
[PKA, glycogen synthase kinase (GSK)3b and casein kinase
(CK)1] phosphorylate GLI proteins, leading to ubiquityla-
tion/proteosome-dependent GLI1 degradation or GLI2 and
GLI3 proteolytic cleavage into repressor forms (GLI2R and
GLI3R). These events are mediated by Cullin1/beta-trans-
ducin repeats-containing proteins (b-TrCP) E3 ubiquitin
ligase complex [1,39]. In contrast, the activation of Hh
signaling inhibits this processing, resulting in full-length
GLI2 and GLI3, which have activator function (GLI3A and
GLI2A) [38]. The balance between activator and repressor
functions of GLI transcription factors determines the status
of the Hh transcriptional program and consequently the
behavior of responding cells.
The fine interplay among post-translational modifications
and intersection with other pathways, such as PI3K–AKT,
has a crucial role in the regulation of GLI activity and in the
generation of their repressor forms [40–42]. In addition to
b-TrCP, for example, other E3 ligases belonging to the really
interesting new gene (RING) (Cullin3/speckle-type POZ pro-
tein (HIB-SPOP)) or homologous to E6-AP carboxy terminus
(HECT) (ITCH) family have been identified to be responsible
for Drosophila and mammalian Ci/GLI proteolysis through
phosphorylation-independent mechanisms [43,44]. Further-
more, acetylation/ubiquitylation interplay, mediated by his-
tone deacetylases (HDACs) and members of Cul3 adaptor
proteins family potassium channel tetramerization domain,
(KCTDs) (KCASH, KCTD containing Cullin3 Adaptor Sup-
pressor of Hedgehog), has been recently discovered as a key
transcriptional checkpoint of GLI function [45,46].
Albeit several aspects of GLI regulation remain unclear,
it is evident the key role of GLI in embryogenesis and adult
homeostasis. Indeed, GLI factors activate the expression of a
number of genes involved in functions related to tissue
development, such as cell proliferation and differentiation
(e.g., CyclinD1 and D2, N-Myc, Wnts, PDGFR, IGF2, FoxM1,
FoxA2, Nkx2.2, FoxF1, Myf5, HES1, and IGFBP3), survival
(Bcl2), self-renewal and cell fate determination (Bmi1 and
Nanog), angiogenesis (VEGF), epithelial–mesenchymal
transition (Snail1, Sip1, Elk1, and Msx2) and tumor cell
invasiveness (Osteopontin) in several tissues [19,47]. Re-
markably, GLI factors control the expression of both GLI1
and PTCH1, thus forming a feedback loop enhancing or
repressing Hh response. Given the broad spectrum of cellu-
lar events under GLI control, dysregulation of GLI genes
could clearly lead to unfavorable developmental and patho-
logical consequences, such as oncogenesis. GLI1 was indeed
the first Hh pathway gene found to be amplified in several
cancers, such as glioblastoma, glial tumors, prostate cancer,
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expression as the only reliable marker of Hh pathway
activity [15,48]. Moreover, the level of GLI1 transcript
can be used to discriminate BCC from certain other skin
tumors [49] and GLI deregulations have been revealed in
MB, the most common malignant pediatric brain tumor.
The primary mediator of Hh signaling, GLI2, has been also
identified as pleiotropic oncogene, whose upregulation
induces genomic instability and a number of the acquired
characteristics of tumor cells [50]. Interestingly, GLI2 is
upregulated in a wide variety of human tumors such as
melanoma [51], prostate cancer [52], BCC [53], and hepato-
cellular carcinoma [54], becoming potentially an attractive
therapeutic target. Noteworthy, several reports have
highlighted noncanonical mechanisms of GLI activation,
in addition or independent of upstream Hh signaling
[26,47,55]. For instance, GLI expression, stability, and/or
transcriptional activity in normal and cancer cells may be
positively modulated via the persistent stimulation of
different growth factor cascades, such as EGF/EGFR
(epidermal growth factor receptor), Wnt/b-catenin, and
the TGF-b1/TGF-bR (transforming growth factor b recep-
tor) system [56]. The aberrant crosstalk among Hh signaling
and these pathways can induce tumor transformation. In
this regard, K-RAS and TGF-b were shown to regulate GLI1
expression in absence of SMO and they collaborate with Hh
signaling to initiate pancreatic ductal adenocarcinoma
(PDAC) development [57]. In contrast, EGFR signaling
modulates Hh/GLI target gene expression during keratino-
cytes transformation inducing activation of JUN/activator
protein-1 (AP1), which cooperates with GLI1 and GLI2
[58]. Moreover, the interaction between Hh and platelet-
derived growth factor (PDGF) signaling has been shown in
cultured murine fibroblasts, BCC cells, and CNS tumors
[59]. Activation of the Hh/GLI signaling was also observed in
Ewing sarcoma family tumors (ESFTs), where the oncogenic
transcription factor Ewing’s Sarcoma/Friend leukemia in-
tegration 1 (EWS/FL1), resulting from the chromosomal
translocation t(11;22), induces directly GLI1 expression
[60]. Furthermore, PI3K/AKT signaling was described to
negatively regulate the degradation of GLI2 and potentiate
GLI1 transcriptional activity [61]. Hh signaling is also
differently modulated by distinct members of the PKC
family: upregulation of aPKCi/l potentiates Hh signaling
by directly phosphorylating and activating GLI1 and be-
cause of aPKCi/l is also an Hh target gene, it sustains a
positive feedback loop contributing to Hh activation [62].
It is important to consider that, whatever alteration
leads to aberrant Hh pathway activation, such as genetic
mutations of pathway components or other SMO-depen-
dent or -independent mechanisms, all trigger the down-
stream effector GLI1. For this reason, GLI factors are
emerging as attractive targets for the development of novel
anticancer drugs. However only a few GLI antagonists
have been identified, most likely due to the lack of struc-
tural details related to GLI activity.
Most effective GLI antagonists developed so far are
herein reviewed and classified based on their mechanism
of action. Direct GLI antagonists act by contacting directly
GLI effectors and blocking their transcriptional functions,
whereas indirect GLI antagonists inhibit GLI functionsthrough mechanisms that control GLI activity, such as
proteolytic degradation or post-translational modifica-
tions.
Indirect GLI antagonists
Cyclohexyl-methyl aminopyrimidines (CMAPs)
A series of CMAPs (Figure 1) have been identified by a
phenotypic screening approach, designed to classify com-
pounds as SMO or non-SMO antagonists. Bassilana and
coworkers have discovered a CMAP chemotype able to
block GLI functions and, through a chemoproteomics strat-
egy, they also have identified the orphan GPCR GPR39 as
the specific target of this molecule [63]. Although the
authors failed to demonstrate the direct binding of CMAP
to GPR39, data document that CMAP is a specific agonist
of this receptor. Indeed, ectopic expression or knockdown
of GPR39 conferred or decreased, respectively, responsive-
ness to CMAP. Interestingly, CMAP analogs were able to
inhibit GLI-activated signaling following overexpression of
GLI1 or GLI2, providing evidence that CMAPs affect Hh
signaling (Table 1). Specifically, CMAPs-activated GPR39
leads to inositol triphosphate production and activation of
mitogen-activated protein kinase (MAPK) pathway, thus
repressing GLI signaling. However, the mechanism by
which GPR39 activation impinges GLI function has not
been elucidated (Figure 2). Since MAPK activation occurs
also via Gi-coupled signaling and b arrestin recruitment,
the discovery of CMAPs/GPR39 axis has identified a new
mechanism for Hh inhibition downstream of SMO, trigger-
ing signaling pathways that cooperate to counteract Hh
activation.
JQ1 and I-BET151
Recently, epigenetic enzymes have emerged as druggable
targets for attenuating the growth of Hh-dependent
tumors [64]. A new class of compounds targeting bromo
and extra C-terminal (BET) bromodomain (BRD) proteins
has been described to specifically affect GLI transcription-
al activity. Members of the BET family proteins (BRD1–4)
are involved in cell cycle progression, chromatin compac-
tion, and chemoresistance. These proteins, through their
bromodomains, bind to acetylated lysines in histones, and
through their interaction with the positive transcription
elongation factor (p-TEFb) stimulate RNA polymerase II
activity and enhance gene expression [65]. Among different
BET enzymes, suggestive evidences identify BRD4 as an
attractive candidate target for developing therapeutics
against Hh-driven tumors. Tang and colleagues have
demonstrated that BRD4 activates Hh signaling in a
ligand-independent manner, finely tuning GLI1- and
GLI2-mediated transcription by direct occupancy of their
promoters. Accordingly, they have identified the BET inhib-
itor JQ1 (Figures 1 and 2) as a potent GLI antagonist that
alters the recruitment of GLI proteins on their target genes,
determining growth arrest and cell death of tumors from
patients with aberrant Hh pathway activation (Table 1).
Importantly, JQ1 also impaired GLI signaling in a context
of acquired resistance to SMO antagonism. Another BRD4
inhibitor, I-BET151 (Figures 1 and 2), has been recently
described to suppress the expression of Hh target genes in a
SMO-independent fashion, thus inhibiting MB cells growth,3
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Figure 1. Indirect GLI antagonists. Chemical structure of the most effective GLI antagonists acting by an indirect mechanism of action. Abbreviations: CMAP, cyclohexyl-
methyl aminopyrimidines; GLI, glioma-associated oncogenes.
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found overexpressed in PDAC cell lines, being able to sus-
tain a high proliferative growth rate and chemoresistance
[67]. All these finding suggest that BET inhibitors can
represent an innovative therapeutic tool for the treatment
of aggressive Hh-dependent tumors besides MB and BCC.
HDAC inhibitors (HDACis)
HDACs are a class of enzymes known as epigenetic readers
that play a key role in the regulation of multiple biological
events. Members of HDACs family are involved in the
control of Hh pathway. GLI1 and GLI2 have been reported
to be acetylated proteins [45,68] and their HDAC-mediated
deacetylation has been described to promote their tran-
scriptional activation. This mechanism sustains a positive
autoregulatory loop through Hh-induced upregulation of
HDAC1 and plays a role in ubiquitylation-dependent con-
trol of GLI1 function. Indeed, a Cul3 E3 ubiquitin ligase
complex, formed by a family of the adaptor proteins
KCASH1, KCASH2, and KCASH3, triggers HDAC1 deg-
radation [45,46]. These findings unveil an integrated
HDAC- and ubiquitin-mediated circuitry, where acetyla-
tion of GLI proteins functions as an unexpected key tran-
scriptional checkpoint of Hh signaling. These data identify
HDACis as Hh antagonists able to prevent transcriptional
activity by inducing GLI1 and GLI2 hyperacetylation
(Figure 2) [41,45,68]. Next to HDAC1, also HDAC5 and
HDAC9 were found to be upregulated in MB, and their
expression was associated with poor prognosis [69]. Inter-
estingly, Dhanyamraju and colleagues have recently
observed that another deacetylase, HDAC6, implicated4in primary cilium biology, is overexpressed in a murine
model of Hh-driven MB. These findings suggest that selec-
tive inhibition of HDAC6 can represents a new therapeutic
approach in the treatment of Hh-dependent malignancies.
Indeed, the specific HDAC6 antagonist, ACY-1215 [70]
(Figures 1 and 2 and Table 1), reduced strikingly in vivo
tumor growth. Hence, HDAC6, despite exerting a dichoto-
mous role (it is required to achieve full pathway activity,
but it has also been described to repress basal Hh target
gene transcription) is a critical player in Hh pathway
regulation, promoting the maximum expression of a subset
of GLI target genes [70]. Since the upregulation of HDACs
has been documented in various types of tumors, the devel-
opment of novel potent and selective HDACi is ongoing. In
this regard, several chemical classes of HDACi are currently
being tested in human cancer therapy. To date, three
HDACi (vorinostat [SAHA], romidepsin and belinostat)
have been approved by the FDA for treating refractory
cutaneous and peripheral T cell lymphoma, while other
HDACis have entered clinical trials in both solid and hema-
tological malignancies [71,72]. More importantly, it has
been reported that SAHA can penetrate the blood–brain
barrier and induces apoptosis in mouse models of MB [73].
Pyrvinium
Recently, the anthelmintic drug pyrvinium (Figure 1) has
been described to affect on Hh signaling by inducing GLI
destabilization [74,75]. In particular, pyrvinium has been
described as a specific activator of CK1a, a kinase that
negatively regulates GLI transcription factors by promot-
ing the processing of GLI3 into repressor form and GLI2
Table 1. Efficacy and in vivo study of GLI antagonists
Compound Assay Efficacya In vivo mouse study Dosage Refs
CMAP-1 TM3 (1 nM Ag1.5) Gliluc-assay 1.1 mM (EC50) n.d. n.d. [63]
CMAP-2 TM3 (1 nM Ag1.5) Gliluc-assay 11.3 mM (EC50) n.d. n.d. [63]
CMAP-3 TM3 (1 nM Ag1.5) Gliluc-assay 0.004 mM (EC50) n.d. n.d. [63]
CMAP-4 TM3 (1 nM Ag1.5) Gliluc-assay 0.12 mM (EC50) n.d. n.d. [63]
CMAP-5 TM3 (1 nM Ag1.5) Gliluc-assay 0.02 mM (EC50) n.d. n.d. [63]
CMAP-6 TM3 (1 nM Ag1.5) Gliluc-assay n.d. n.d. n.d. [63]
CMAP-7 TM3 (1 nM Ag1.5) Gliluc-assay 0.01 mM (EC50) n.d. n.d. [63]
CMAP-8 TM3 (1 nM Ag1.5) Gliluc-assay 0.05 mM (EC50) n.d. n.d. [63]
CMAP-9 TM3 (1 nM Ag1.5) Gliluc-assay 0.2 mM (EC50) n.d. n.d. [63]
I-BET151 Shh-Light2 cells (SAG)/firefly
luciferase
31 nM (IC50) Allograft of spontaneous
MBs from Ptch+/ mice
30 mg/kg [66]
JQ-1 Cell viability in Smo WT -MB and
Med1-MB cells
~50–150 nM (IC50) Allograft of Med1-MB
cells; SmoWT-MB or
SmoD477G-MB cells.
Allograft model of Ptch+/;
K14-creER2; p53flox/flox–
derived mouse BCC cells
50 mg/kg [109]
HDiA and HDiB Shh-Light2 cells (SAG)/firefly
luciferase
n.d. n.d. n.d. [45]
ACY-1215 Shh-Light2 cells (SAG)/firefly
luciferase
n.d. Allograft of primary
SmoA1 MB cells (MB99-1
cells)
50 mg/kg [70]
Pyrvinium Shh-Light2cells (SAG or SHH)/
firefly luciferase
~10 nM (IC50) (a) Allograft of
spontaneous MBs from
Ptch+/ mice
(b) APCmin mice
(a) 0.8 mg/kg
5 mg/kg
(b) 25 mg/kg
[74,75]
GANT58 Shh-Light2 cells (SAG)/firefly
luciferase
~5 mM (IC50) Xenograft of 22Rv1
prostate cancer cells
50 mg/kg [81]
GANT61 Shh-Light2 cells (SAG)/firefly
luciferase
~5 mM (IC50) Xenograft of 22Rv1
prostate cancer cells
Xenograft of Huh7
hepatocellular carcinoma
cells
Orthotopic xenograft of
CFPAC-1 pancreatic
cancer cells
50 mg/kg [81,86,91]
HPI-1 GLI1 overexpressing NIH 3T3
cells/firefly luciferase
6 mM (IC50) Subcutaneous and
orthotopic xenografts of
Huh7 hepatocellular
carcinoma cells
30 mg/kg [100,101]
HPI-2 GLI1 overexpressing NIH 3T3
cells/firefly luciferase
>30 mM (IC50) – – [100]
HPI-3 GLI1 overexpressing NIH 3T3
cells/firefly luciferase
>30 mM (IC50) – – [100]
HPI-4 GLI1 overexpressing NIH 3T3
cells/firefly luciferase
>30 mM (IC50) – – [100]
ATO NIH 3T3 (ShhN) Gliluc-assay 0.7 mM (IC50) (a) Allograft of primary
MBs from Ptch+/p53/
mice
(b) Allograft of BCC tumor
derived from
Ptch+/; K14-creER2;
p53flox/flox
(a)2.5–10 mg/kg
(b) 7.5 mg/kg
[92,94]
GlaB GLI1-overespressing HEK293T
cells/firefly luciferase
12 mM (IC50) (a) Allograft of
spontaneous MBs from
Ptch+/ mice
(b) Orthotopic xenograft of
Daoy MB cells
(c) Allograft of ASZ001
BCC cells
(a)–(b)
35 mg/kg
(c) 50 mg/kg
[106]
aEfficacy is expressed as EC50 or IC50 as reported in parentheses. n.d., not determined/unknown.
Review Trends in Pharmacological Sciences xxx xxxx, Vol. xxx, No. x
TIPS-1241; No. of Pages 12
5
PT
CH
Hh
SMO
aPKCi
HDACi
HDAC
HDAC
BRD4
TAF9
PKA
CMAPs
CK1
Pyrvinium
GPR39
Eggmanone
imiquimod
GLI1
GLI1 GLI2
FN1-8
Hh Target
    genes
GLI2
?
?
i.e. HDiA-B
ACY-1215
JQ1
I-BET151
i.e. PSI
aPKC
TRENDS in Pharmacological Sciences 
Figure 2. Mechanism of Hh inhibition by indirect GLI antagonists. CMAPs activate the orphan receptor GPR39, which represses GLI signaling through a not yet elucidated
mechanism. Pyrvinium is an activator of CK1 kinase, while eggmanone and imiquimod are PKA activators; these molecules negatively regulate GLI transcription factors by
promoting GLI2 repressor form and Gli1 degradation. HDACi, such as HDiA-B (HDAC1-2i) or ACY-1215 (HDAC6i) inhibit HDAC-mediated GLI deacetylation, which is required
for GLI transcriptional activation. JQ1 and I-BET151 inhibit BRD4, which activates GLI1 and GLI2 transcription by direct occupancy of their promoters. PSI inhibits aPKC,
which promotes GLI1 binding to DNA. FN1-8 affects GLI-mediated transcriptional activity by inhibiting GLI1 and GLI2/TAF9 interaction. Abbreviations: aPKC, activated
protein kinase C; BRD4, bromodomain-containing protein 4; CK1, casein kinase 1; CMAPs, cyclohexyl-methyl aminopyrimidines; FN1-8,; GLI, glioma-associated oncogenes;
GPR 39, G-protein-coupled receptor 39; HDACi, histone deacetylase inhibitor; Hh, Hedgehog; PKA, protein kinase A; PTCH, PATCHED; SMO, SMOOTHENED; TAF9, TBP
(TATA-box binding protein)-associated factor 9.
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pyrvinium attenuates Hh-dependent MB cell proliferation
downstream of SMO, both in vitro and in vivo (Table 1).
This occurs as a consequence of its potent efficacy in down-
regulation of GLI1 and PTCH expression also in a context
of hyperactivation of the Hh pathway, resulting from the
loss of the negative regulator SUFU or overexpression of
GLI proteins. Moreover, pyrvinium strongly suppressed
Hh signaling induced by the oncogenic SMO mutant, which
instead showed resistance to the treatment with vismode-
gib. Anti-SMO resistance indicates the presence of by-
stander co-regulatory mechanisms of the Hh pathway and
suggests that their targeting may synergize with Hh inhibi-
tory drugs [29]. Indeed, PI3K/AKT inhibitors revert anti-
SMO resistance, such as that induced by LDE225 compound
[33]. Further, the ability of the mammalian target of rapa-
mycin (mTOR)/protein-chinasi 1 p70-S6 (S6K1)-mediated
phosphorylation and activation of GLI1 might explain the
effect of AKT/PI3K inhibitors because of their ability to
downregulate mTOR function [77].
Eggmanone, imiquimod, and other SMO-independent
antagonists of GLI
The SMO antagonist vismodegib recently approved by the
FDA for the treatment of BCC, causes frequently resis-
tance and severe side effects. Thus, the discovery of novel6clinical strategies for BCC therapy is increasingly becom-
ing important. In this regard, new compounds, eggmanone
and imiquimod, which both target Hh signaling through
PKA activation, are under clinical investigation. Eggma-
none (Figure 1) is a small molecule identified by an in vivo
chemical genetic screening of 30 000 others compounds for
their ability to reproduce the Hh-null phenotype in zebra-
fish embryo. This molecule affects some typical structural
features such as ventral tail curvature, small eyes, loss of
pectoral fins, enlarged rounded somites, loss of neurocra-
nial chondrogenesis and impaired slow muscle formation
[78]. Specifically, in vitro studies show that eggmanone
antagonizes Hh signaling by inhibition of phosphodiester-
ase (PDE)4D3, thus determining an increase of cAMP
levels (Figure 2). This event leads to selective activation
of PKA at the base of the primary cilium, a PKA-localiza-
tion required to promote GLI processing. Imiquimod
(Figure 1) is a synthetic nucleoside analog of the imidazo-
quinoline family, recently approved for topical treatment of
small superficial BCCs. This molecule counteracts Hh
signaling downstream of SMO by inducing PKA activity
(Figure 2) with consequent GLI2/3 phosphorylation and
their cleavage into repressor forms [79]. Other compounds
have been identified to impinge the Hh pathway by target-
ing proteins and/or interactors that modulate GLI factors
activity. For instance, rapamycin inhibits GLI1 functions
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Figure 3. Direct GLI antagonists. Chemical structure of the most effective GLI antagonists acting by a direct mechanism of action. The putative mechanism of GANT61
hydrolytic degradation is also reported. Abbreviations: ATO, arsenic trioxide; GlaB, Glabrescione B; GLI, glioma-associated oncogenes; GANT, GLI antagonist; HPI,
Hedgehog pathway inhibitors.
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duced by tumor necrosis factor (TNF)a and mTOR/S6K1 in
esophageal adenocarcinoma cells [77]. FN1-8, a synthetic
small molecule comprising a pyrazoline structure (Figure 1),
strongly reduces GLI-mediated transcriptional activity by
disrupting the interaction of both GLI1 and GLI2 with TBP
(TATA box-binding protein)-associated factor (TAF)9, a
transcription coactivator (Figure 2). Noteworthy, FN1-8
was able to suppress the proliferation of lung cancer cells
in vitro and in vivo and to inhibit the cell growth of numerous
cancer cells that express high GLI levels, including prostate,
pancreatic, colon cancer, and glioma [80].
Direct GLI antagonists
GLI antagonist 61 (GANT61)
In 2007, a cellular screen for small molecule inhibitors of
GLI1-mediated transcription led to the identification of
GANT58 and GANT61 (Figure 3) as the first GLI antago-
nists [81]. GANT61 proved to counteract GLI-mediated
tumor growth more efficiently than GANT58, becoming
therefore the lead candidate for further investigations and
the most valuable tool for pharmacological Hh pathway
inhibition. Although its mechanism of action has not been
elucidated and no records of preclinical or clinical studies
are available, GANT61 is the reference GLI1/GLI2 antag-
onist in many biological and drug design studies. GANT61
inhibits Hh signaling by impairing GLI1- and GLI2-medi-
ated transcription in vitro and in vivo, affecting the GLI1/
DNA interaction only in living cells probably by inducingpost-translational modifications of GLI1 (Figure 4)
[81]. Moreover, GANT61 is poorly stable at physiological
conditions, and quickly hydrolyzes into a benzaldehyde
species (inactive against Hh signaling) and a diamine
derivative (Figure 3), which has showed the same efficacy
as GANT61 in inhibiting GLI-mediated transcription [82].
GANT61 has been successfully used to inhibit the Hh–
GLI1 axis at the GLI1 and/or GLI2 level in several cancer
cells, CSCs, and tumor animal models, such as pancreatic,[83]
prostate and lung cancer [81,84], colon [85] and hepatocellular
carcinoma (Table 1) [86], as well as against tumors for which
the role of GLI transcription was not elucidated before,
including ovarian cancer [87], esophageal adenocarcinoma
[88], and melanoma CSCs [89], emphasizing the therapeutic
potential of GANT61. Finally, GANT61 has been used to
monitor the relationship between specific GLI targeting
and autophagy. Indeed, GANT61 has been found to induce
cancer suppressing autophagic processes in PDAC and hepa-
tocellular carcinoma cells, whereas prosurvival autophagy
has been observed in neuroblastoma cells [86,90,91].
Arsenic trioxide (ATO)
ATO (Figure 3) is an FDA-approved drug for second-line
treatment of acute promyelocytic leukemia that functions
by binding to cysteine residues of proteins involved in
MAPK, nuclear factor k-light-chain-enhancer of activated
B cells (NF-k,B), c-Jun N-terminal kinases (JNK) and other
pathways. In 2010, Kim and collaborators observed that
ATO antagonizes the Hh pathway in vitro and in vivo by7
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Figure 4. Mechanism of Hh inhibition by direct GLI antagonists. GANT61 inhibits GLI-mediated transcription by an unclear mechanism (most likely by inducing post-
translational modifications of GLI). ATO affects ciliary accumulation of GLI2 and enhances its degradation after longer treatment regimens. HPI-1 has been observed to
target post-translational events of GLI processing/activation downstream of SMO. HPI2 and HPI-3 seem to alter the cellular trafficking of GLI1 and to increase the stability of
GLI2. GlaB inhibits GLI1/DNA interaction by its ability to bind GLI1 zinc-finger domain. Abbreviations: ATO, arsenic trioxide; GANT, GLI antagonist; GlaB, Glabrescione B;
GLI, glioma-associated oncogenes; Hh, Hedgehog; HPI, Hedgehog pathway inhibitors; PTCH, PATCHED; SMO, SMOOTHENED.
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[92]. ATO has been observed to inhibit ciliary accumulation
of GLI2 in the short term, and to enhance GLI2 degradation
after a prolonged incubation time in MB cells (Figure 4).
In 2011, Beauchamp et al. showed that ATO inhibits Hh
signaling by interacting directly with GLI1, without altering
GLI1/DNA interaction or modifying GLI1 cellular traffick-
ing and stability [93]. Although these works have proposed
rather different mechanisms, they have clearly indicated
that ATO, used alone or in combination with other antican-
cer drugs, may represent a valuable therapeutic option to
treat Hh-dependent tumors, particularly those harboring
drug-resistant SMO mutations [92–94]. Accordingly, itra-
conazole, an FDA-approved triazole antifungal agent, oper-
ates on the Hh signaling at the level of SMO at a different
site than cyclopamine. Single and combined therapy with
itraconazole and ATO inhibits cellular growth of MB and
BCC in vitro and in vivo, both in wild type and in drug-
resistant SMOD477G mice. In fact, the problem of resistance
establishment to cyclopamine or cyclopamine mimics, due to
some human SMO point mutations (such as D473H and
E518K), is becoming even more prevalent. These character-
istics strongly encourage the synergic therapy with itraco-
nazole and ATO for the treatment of de novo Hh-dependent
tumors or those with acquired resistance to cyclopamine
[94]. Following these studies, the efficacy of ATO in target-
ing GLI transcription factors has been investigated in MB
[93–95], pleural mesothelioma [96], malignant rhabdoid
tumors [97], osteosarcoma [98], and many others cancer8types. Furthermore, growing evidence points to a role for
ATO as a modulator of the proliferation and differentiation
of cancer cells progenitors by impacting on Hh or Notch
signaling [99]. It is worth mentioning that a pilot clinical
trial study to monitor the efficacy of ATO in treating patients
with BCC started in late 2013 (https://clinicaltrials.gov/
show/NCT01791894).
Hedgehog pathway inhibitors (HPIs)
A cell-based high-throughput screening performed by
Hyman and coworkers led to the identification of some
chemically unrelated small molecules (namely, HPI-1,
HPI-2, HPI-3, and HPI-4) (Figure 3), which inhibit the
Hh pathway downstream of SMO by directly antagonizing
GLI (Table 1) [100]. Collectively, HPIs have demonstrated
multiple and different mechanisms of action (Figure 4).
HPI-1 has been observed to target post-translational
events of GLI processing/activation downstream of SMO
and has been shown to inhibit the growth of hepatocellular
carcinoma and MB cells expressing drug-resistant SMO,
especially when encapsulated in nanoparticles (Table 1)
[101]. In contrast, HPI-2 and HPI-3 have been associated
with an altered trafficking of GLI1 and with increased
stability of GLI2, which in turn impairs the conversion
of full-length GLI2 to a transcriptional activator. Finally,
HPI-4 has been found to perturb ciliogenesis by an unclear
mechanism, and to decrease human chondrosarcoma cell
proliferation, invasion, and migration [102]. Only HPI-1
and HPI-4 have been shown to inhibit the proliferation of
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Figure 5. Structural details of GLI1/DNA interaction. (A) X-ray crystallographic structure of GLI1 ZF domain in complex with DNA, PDB ID: 2GLI; crystallographic water
molecules are shown as red dots. (B) Details of the predicted binding pose of GlaB (cyan stick) within ZF4 and ZF5. Key residues for GLI1 transcriptional functions are shown
as green sticks. Metal ions are shown as yellow spheres. Abbreviations: GlaB, Glabrescione B; GLI, glioma-associated oncogenes; ZF, zinc finger.
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of HPIs on Hh signaling have highlighted the complexity of
Hh/GLI regulation and have offered different opportu-
nities for pharmacological modulation of aberrant Hh sig-
naling even though their efficacy in vivo has not been
evaluated yet.
Glabrescione B (GlaB)
Natural products have historically had a significant impact
in Hh modulation (i.e., cyclopamine). Among the various
chemical classes of natural products, isoflavones have dis-
played a noticeable pharmacophoric preference for Hh
targets, as underlined by genistein and its derivatives in
differentiated pancreatic cancer cells and CSCs [103,104].
Recently, our own research group has established a multi-
disciplinary drug discovery program focusing on the
identification of natural products as direct GLI1 antago-
nists. Starting from the crystallographic structure of the
GLI1-ZF domain in a complex with DNA [105], we have
performed a mixed computational and experimental struc-
ture-based study to identify K350, R354, R380, and K381
residues as the strongest hot spots for GLI1/DNA interac-
tion and transcriptional functions (Figure 5) [106]. This
information was subsequently used to discover pharmaco-
logical agents able to interfere with this basic process. By
virtual screening of a natural compounds library against
these hot spots and monitoring Hh inhibition at GLI1 level,
we have identified GlaB (Figures 3 and 5B, Table 1), an
isoflavone naturally occurring in Derris glabrescens, as a
potent Hh inhibitor acting downstream of SMO. NMR and
(EMSA) Electrophoretic Mobility Shift Assay experiments
have confirmed that GlaB binds to GLI1 in correspondence
of ZF4 and ZF5 affecting GLI1/DNA interaction and also
emphasizing the role of K350 and K340 in this event [106]
(Figures 4 and 5). GlaB has proved to inhibit Hh signaling
in multiple cancer cells and CSCs, as well as the in vivo
MB and BCC tumor growth in orthotopic xenograft mice
and in allograft mice models, respectively (Table 1) [106].
Our work has raised the importance to investigate the
mechanism of GLI1-mediated transcription, and the iden-
tification of the structural requirements of GLI1/DNA
interaction have highlighted their relevance for pharma-
cological interference of GLI1 signaling by direct GLI1
antagonists.Concluding remarks
A critical goal in Hh-dependent tumor biology is the dis-
covery of novel small molecules blocking the pathway at
a downstream level. The rationale for the development of
these pharmacological agents is based on (i) the heteroge-
neity of molecular defects sustaining the pathway activa-
tion; and (ii) the need to overcome the resistance to
clinically available SMO antagonists.
Targeting GLI effectors represents a promising thera-
peutic strategy for cancer treatment. This is particularly
relevant for certain tumors, such as MB, since, although
classified into four distinct molecular groups (Hh- or Wnt-
type and 3rd or 4th), common signals, such as placental
growth factor (PIGF)/neuropilin axis, responsible of GLI1
upregulation, are shared by all subtypes and are important
for tumor growth [107].
Transcription factors are generally considered as chal-
lenging targets in drug discovery for many different rea-
sons, including the lack of deep hydrophobic pockets that
accommodate small molecules and the highly charged
surface. Nevertheless, big pharmaceutical companies are
currently running Phase I clinical trials with small mole-
cules targeting transcription factors such as Notch (Bristol-
Myers Squibb and Ely Lilly) and p53 (Roche and Sanofi)
[108], although no drugs have been approved yet by the
FDA. Beside these targets, cMYC, NF-kB, signal transducer
and activator of transcription (STAT)3, STAT5, AP1, hyp-
oxia-inducible factor (HIF1), and GLI1 are among the most
promising transcription factors for the development of
new anticancer drugs. GLI functions are finely tuned by
a number of molecular interactions and postsynthetic
modifications (i.e., GLI1 phosphorylation, gene copy number
amplification, BRD4-driven epigenetic activation, deubiqui-
tylation, deacetylation, or activation by aPKCi,/k or p70S6K
or RAS/ERK) that, if dysregulated, are responsible for
the resistance to anti-SMO drugs frequently observed in
Hh-driven tumor initiation, progression and relapse [16,26,
109]. Interestingly, GLI-processing and activating post-
translational events are pharmacologically targetable, even
though by means of combination therapies. For this reason,
the challenge in this field is the understanding of the
molecular mechanisms that regulate GLI-mediated tran-
scription. In this regard, the recently reported identification
of the structural requirements of GLI1/DNA interaction,9
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capable of inhibiting Hh pathway by directly targeting GLI
[106]. The discovery of the natural compound, GlaB, able to
impair Hh oncogenic activity by inhibiting GLI1/DNA in-
teraction, provides a proof-of-principle for the therapeutic
relevance of such an approach, focused on the unique down-
stream GLI1 transcriptional effector rather than on multi-
ple upstream oncogenic deregulated signals. Since the GLI
proteins share highly conserved sequence of their ZF do-
main, targeting GLI1/DNA interaction could also interfere
with GLI3/DNA binding, counteracting the GLI3 repressor
function and resulting in severe side effects. However, the
use of Hh antagonists is thought in a context of aberrant Hh
pathway activation, where GLI repressor forms are absent,
so bypassing the possibility of nonspecific effects on negative
regulatory activity of GLI factors. Therefore, drugs specifi-
cally designed to modulate GLI/DNA interaction would
provide valuable insights for developing and optimizing
GLI antagonists, which would promise a more effective
treatment of Hh-dependent tumors.
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